Experience of using long-acting testosterone undecanoate in hypogonadism, obesity and metabolic syndrome in men
https://doi.org/10.14341/2071-8713-5071
Abstract
The paper outlines the author's experience on the efficacy and safety of androgen therapy of metabolic syndrome and obesity in men with hypogonadism. The study used testosterone undecanoate therapy that reduced body fat and the severity of the other components of the metabolic syndrome, improved sexual function without causing severe side effects. A number of patients on therapy observed suppression of spermatogenesis, which prevents the use of the drug in the reproductive rehabilitation.
References
1. Андрология. Мужское здоровье и дисфункция репродуктивной системы. Под ред. Э Нишлага, Г.М. Бере. М., 2005. 554 с.
2. Дедов ИИ, Курбатов ДГ, Роживанов РВ, Лепетухин АЕ, Дубский СА, Гончаров НП. Применение пролонгированного препарата тестостерона ундеканоата при синдроме гипогонадизма и его осложнениях у мужчин. Урология 2011;6:54–61.
3. Калинченко СЮ, Роживанов РВ. Особенности лечения мужчин с ожирением. Ожирение и метаболизм 2005;3:39–42.
4. Тишова Ю. А., Калинченко С. Ю. Роль коррекции гипогонадизма в лечении метаболического синдрома у мужчин и аспекты безопасности терапии препаратом тестостерона пролонгированного действия (результаты двойного слепого рандомизированного плацебо-контролируемого исследования). Ожирение и метаболизм. 2010;2:36–43.
5. Armellini et al. Hormones and body composition in humans: clinical studies. Int J Obes Relat Metab Disord. 2000 Jun;24 Suppl 2:S18–21.
6. Cunningham GR. Management of male aging: which testosterone replacement therapy should be used? The Aging Male 2000;3:203–209.
7. Dobs et al. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system. J Clin Endocrinol Metab. 2001 Mar;86(3):1026–33.
8. Finley MR, Curruthers ME. Androgens, the prostate and safety of testosterone treatment. The Aging Male. 2006;9(1)- P. – 4.
9. Gu YQ, Wang XH, Xu D, Peng L, Cheng LF, Huang MK, Huang Z-J, Zhang GY. A Multicenter Contraceptive Efficacy Study of Injectable Testosterone Undecanoate in Healthy Chinese Men. J Clin Endocrinol Metab. 2003;88(2):562–568.
10. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K; DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004 May 24;164(10):1066–76.
11. Laaksonen et al. Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol 2003 Dec;149(6):601–8.
12. Leenen R, van der Kooy K, Seidell J.C. et al. Visceral fat accumulation in relation to sex hormones in obese men and women undergoing weight loss therapy. J. Clin. Endocrinol. Metab. 1994;78:1515–1520.
13. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care. 2000 Apr;23(4):490–4.
14. Svartberg J et al. Waist circumference and testosterone levels in community dwelling men. The Tromsø study. Europ J Epidemiol 2004;19(7):657–63.
15. Tsai EC, Boyko EJ, Leonetti DL, Fujimoto WY. Low serum testosterone level as predictor of increased visceral fat in Japanese-American men. Int J Obes Relat Metab Disord 2000;24:485–91.
16. Yassin A, Saad F. Long-Acting Testosterone Ester injection as a First Line Therapy in hypogonadal patients with Erectile Dysfunction. Int. J. Androl. 2005;28 (Suppl.1):53.
17. Zitzmann M, Mattern A, Hanisch J, Gooren L, Jones H, Maggi M. A Study on the tolerability and Effectiveness of Injectable Testosterone Undecanoate for the Treatment of Male Hypogonadism in a Worldwide Sample of 1,438 Men. J. Sex. Med 2012;19. doi: 10.1111/j.1743-6109.2012.02853.x.
Review
For citations:
Experience of using long-acting testosterone undecanoate in hypogonadism, obesity and metabolic syndrome in men. Obesity and metabolism. 2013;10(1):43-46. (In Russ.) https://doi.org/10.14341/2071-8713-5071
Views:
3775
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
